Navigation Links
Torbjorn Bjerke Appointed as new CEO for Karolinska Development

Torbjorn Bjerke Appointed as new CEO for Karolinska Development -- STOCKHOLM, August 23, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Torbjorn Bjerke Appointed as new CEO for Karolinska Development


STOCKHOLM, August 23, 2010 /PRNewswire/ -- Torbjorn Bjerke has been appointed as new CEO for Karolinska Development. He is currently CEO for Orexo, a position he has held since 2007. Torbjorn Bjerke succeeds Conny Bogentoft who will assume the position as Chief Scientific Officer for Karolinska Development.

Starting its operation in 2003, Karolinska Development has rapidly become one of the leading companies within early pharmaceutical development in Europe. Investments by Karolinska Development have focused on developing its portfolio companies to proof of concept. Karolinska Development has now entered a next phase where the company will seek external partners for some of its portfolio companies while preparing for an initial public offering.

"With his solid background as a commercial leader, Torbjorn Bjerke has the right profile for the role as CEO for Karolinska Development. He has vast experience from leading and developing early research-based companies as well as a listed pharmaceutical company. Torbjorn's experience in business development and his demonstrated ability in negotiating and implementing collaborations with international partners will be of great value to us, our shareholders and our portfolio companies," says Hans Wigzell, Chairman of Karolinska Development.

Torbjorn Bjerke has held the position as CEO for Orexo since 2007. He will assume the position as CEO for Karolinska Development when his successor has been appointed. Conny Bogentoft, who has held the position as CEO for Karolinska Development since its inception in 2003, will become Chief Scientific Officer with overall responsibility for the future development of Karolinska Development's portfolio.

"I look forward to my new role as CEO for Karolinska Development, and to lead one of the most exciting pharmaceutical companies in Europe to further success and a future IPO," says Torbjorn Bjerke.


About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products.

For further information, please contact: Hans Wigzell, Chairman of the board, Karolinska Development Tel: +46(0)705-76-05-39, e-mail: Conny Bogentoft, CEO, Karolinska Development Tel: +46(0)706-88-61-43, e-mail: Torbjorn Bjerke, appointed CEO, Karolinska Development Tel: +46(0)708-66-19-90, e-mail:

SOURCE Karolinska Development AB PUBL
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shawn Cross Appointed CEO of Burrill Merchant Banking Group
2. New President and CEO appointed at Ocean Nutrition Canada Limited
3. Professor Sander van Deventer Appointed to Supervisory Board of AMT
4. New Board Director Appointed
5. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
6. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
7. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
8. Lori Kahler Appointed President of The RC Insight Group
9. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
10. FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
11. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
Post Your Comments:
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
Breaking Biology Technology:
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
(Date:10/23/2015)... DUBLIN , Oct. 23, 2015 Research ... of the "Global Voice Recognition Biometrics Market 2015-2019" ... --> --> The global voice recognition ... during 2014-2019. --> ... 2015-2019, has been prepared based on an in-depth market ...
(Date:10/22/2015)...  Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter ended September 30, 2015.  --> ... $4.0 million, a decrease of 33% compared to $6.0 million in ... of 2015 was $2.2 million, or $0.10 per diluted share, which ... same period a year ago.  --> ...
Breaking Biology News(10 mins):